Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CAO Theodore Alan Huizenga Sells 970 Shares of Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CAO Theodore Alan Huizenga sold 970 shares of the stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $37.15, for a total value of $36,035.50. Following the completion of the sale, the chief accounting officer now directly owns 23,777 shares of the company’s stock, valued at $883,315.55. The sale was disclosed in a filing with the SEC, which is available at this link.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE opened at $38.79 on Thursday. The company has a market capitalization of $2.77 billion, a PE ratio of -3.79 and a beta of 0.87. Ultragenyx Pharmaceutical Inc. has a one year low of $33.36 and a one year high of $54.98. The company’s fifty day moving average price is $40.54 and its 200 day moving average price is $43.30.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($2.25) earnings per share for the quarter, missing the consensus estimate of ($2.11) by ($0.14). The business had revenue of $108.30 million for the quarter, compared to analyst estimates of $107.10 million. Ultragenyx Pharmaceutical had a negative return on equity of 220.54% and a negative net margin of 178.91%. Ultragenyx Pharmaceutical’s revenue for the quarter was up 21.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.26) EPS. Analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -8.65 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Evercore ISI raised shares of Ultragenyx Pharmaceutical from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $60.00 to $80.00 in a research report on Tuesday, June 6th. Citigroup lifted their target price on shares of Ultragenyx Pharmaceutical from $130.00 to $133.00 in a research note on Wednesday, June 7th. Wedbush lowered their price target on shares of Ultragenyx Pharmaceutical from $49.00 to $47.00 in a report on Friday, August 4th. HC Wainwright reiterated a “buy” rating and set a $82.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 1st. Finally, Morgan Stanley reissued an “overweight” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, August 4th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $81.21.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently modified their holdings of RARE. Vanguard Group Inc. grew its position in Ultragenyx Pharmaceutical by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 6,161,866 shares of the biopharmaceutical company’s stock worth $255,163,000 after purchasing an additional 27,722 shares during the last quarter. BlackRock Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 4.0% in the 2nd quarter. BlackRock Inc. now owns 5,067,027 shares of the biopharmaceutical company’s stock worth $233,742,000 after acquiring an additional 193,671 shares during the period. RTW Investments LP grew its holdings in shares of Ultragenyx Pharmaceutical by 7.7% during the 1st quarter. RTW Investments LP now owns 4,270,996 shares of the biopharmaceutical company’s stock worth $171,267,000 after purchasing an additional 304,081 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Ultragenyx Pharmaceutical by 17.1% during the first quarter. Wellington Management Group LLP now owns 3,370,245 shares of the biopharmaceutical company’s stock valued at $244,747,000 after purchasing an additional 492,842 shares during the period. Finally, Avidity Partners Management LP raised its stake in shares of Ultragenyx Pharmaceutical by 45.7% in the fourth quarter. Avidity Partners Management LP now owns 2,990,000 shares of the biopharmaceutical company’s stock valued at $138,527,000 after purchasing an additional 938,400 shares in the last quarter. Institutional investors and hedge funds own 96.37% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.